ArticleScientific reports2022
Trends of kidney cancer burden from 1990 to 2019 in European Union 15 + countries and World Health Organization regions.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Epidemiological Trends and Burden of Adult Kidney Cancer in Saudi Arabia: A 42-Year Retrospective Analysis (1982-2023).Cancer reports (Hoboken, N.J.) · 2026Observational
- Beyond angiogenesis: integrating ferroptosis and metabolic rewiring for next-generation RCC therapy.Frontiers in oncology · 2026Review
- Long-term environmental background radiation is associated with urinary tract cancer incidence: A population-based study from Finland.Cancer epidemiology · 2025Article
- Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy.Current oncology (Toronto, Ont.) · 2025Observational
- Article
- PRSS53 is a potential novel biomarker related to prognosis and immunity in clear cell renal cell carcinoma.Discover oncology · 2025Article
- Prognosis impact and clinical findings in renal cancer patients: comparative analysis between public and private health coverage in a cross-sectional and multicenter context.Cancer causes & control : CCC · 2025Article
- Evolving trends in lung cancer risk factors in the ten most populous countries: an analysis of data from the 2019 Global Burden of Disease Study.EClinicalMedicine · 2025Article
- Psychometric properties of the Chinese version of scales of knowledge, attitude, and practice of self-care for patients with arteriovenous fistula: a translation and verification study.Frontiers in public health · 2025Article
- Article
- Kidney cancer in the Middle East and North Africa region: a 30-year analysis (1990-2019).Scientific reports · 2024Article
- Liquid biopsy for Renal Cell Carcinoma: A comprehensive review of techniques, applications, and future prospects.Kidney cancer (Clifton, Va.) · 2024Article
- Burden of AML, 1990-2019: Estimates From the Global Burden of Disease Study.JCO global oncology · 2023Article
- Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities.JCO global oncology · 2023Article
- Epidemiological Trends of Kidney Cancer Along with Attributable Risk Factors in China from 1990 to 2019 and Its Projections Until 2030: An Analysis of the Global Burden of Disease Study 2019.Clinical epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, variability in the incidence and mortality of kidney cancer (KC) has been reported. This study aimed to compare trends in incidence, mortality, and disability-adjusted life years (DALY) of KC between the European Union (EU) 15 + countries and 6 World Health Organization (WHO) regions. The data of KC Age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), and age-standardized DALYs were extracted from the Global Burden of Disease database. Joinpoint regression was employed to examine trends. From 1990 to 2019, the ASIR increased in most countries except for Luxembourg (males), the USA (females) and Austria and Sweden (both sexes). ASIR increased across all 6 WHO regions for both sexes except for females in Americas. The ASMR increased in 10/19 countries for males and 9/19 for females as well across most WHO regions. The mortality-to-incidence ratio (MIR) decreased in all countries and WHO regions. Trends in DALYs were variable across countries and WHO regions. While the incidence and mortality from KC rose in most EU15 + countries and WHO regions from 1990 to 2019, the universal drop in MIR suggests an overall improvement in KC outcomes. This is likely multifactorial, including earlier detection of KC and improved treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.